Molecular structure of Ximelagatran, CAS Number: 192939-46-1
Ximelagatran (CAS 192939-46-1)
Alternate Names:
Exanta; H 376/95; N-[(1R)-1-Cyclohexyl-2-[(2S)-2-[[[[4-[(hydroxyamino)iminomethyl]phenyl]methyl]amino]carbonyl]-1-azetidinyl]-2-oxoethyl]glycine Ethyl Ester
Application:
Ximelagatran is a direct thrombin inhibitor
CAS Number:
192939-46-1
Molecular Weight:
473.57
Molecular Formula:
C24H35N5O5
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.
* Refer to Certificate of Analysis for lot specific data.
QUICK LINKS
Ordering Information
Description
Technical Information
Safety Information
SDS & Certificate of Analysis
Ximelagatran is an direct thrombin inhibitor that acts as an anticoagulant by preventing the formation of blood clots. It works by targeting and inhibiting the activity of thrombin, a key enzyme in the blood coagulation cascade. This inhibition ultimately prevents the conversion of fibrinogen to fibrin, which is necessary for the formation of blood clots. Ximelagatran is metabolized to its active form, melagatran. This active form exerts its anticoagulant effects.
Ximelagatran (CAS 192939-46-1) References
- Two new antithrombotic agents (fondaparinux and ximelagatran) and their implications in anesthesia. | de Moerloose, P. and Boehlen, F. 2002. Can J Anaesth. 49: S5-10. PMID: 12557410
- [Ximelagatran: a promising new drug for oral anticoagulation]. | Scardi, S. and Giansante, C. 2004. Monaldi Arch Chest Dis. 62: 34-9. PMID: 15211735
- Ximelagatran: a new antithrombotic option in atrial fibrillation. | Dager, WE. 2004. J Cardiovasc Pharmacol Ther. 9: 151-62. PMID: 15378135
- Ximelagatran: oral direct thrombin inhibition as anticoagulant therapy in atrial fibrillation. | Halperin, JL. 2005. J Am Coll Cardiol. 45: 1-9. PMID: 15629364
- Costs and effectiveness of ximelagatran for stroke prophylaxis in chronic atrial fibrillation. | O'Brien, CL. and Gage, BF. 2005. JAMA. 293: 699-706. PMID: 15701911
- The effects of ximelagatran and warfarin on the prophylaxis of a caval vein thrombosis and bleeding in the anaesthetized rat. | Carlsson, S. and Elg, M. 2005. Blood Coagul Fibrinolysis. 16: 245-9. PMID: 15870543
- Ximelagatran compared with warfarin for the prevention of systemic embolism and stroke. An imputed placebo analysis. | Berry, C., et al. 2005. Cardiovasc Drugs Ther. 19: 149-51. PMID: 16025234
- Trials and tribulations of non-inferiority: the ximelagatran experience. | Kaul, S., et al. 2005. J Am Coll Cardiol. 46: 1986-95. PMID: 16325029
- Influence of erythromycin on the pharmacokinetics of ximelagatran may involve inhibition of P-glycoprotein-mediated excretion. | Eriksson, UG., et al. 2006. Drug Metab Dispos. 34: 775-82. PMID: 16455803
- Ximelagatran/melagatran against conventional anticoagulation: a meta-analysis based on 22,639 patients. | Testa, L., et al. 2007. Int J Cardiol. 122: 117-24. PMID: 17222926
- [Antithrombotic therapy in atrial fibrillation with ximelagatran: can it be an alternative to warfarin?]. | Selçuk, H., et al. 2007. Anadolu Kardiyol Derg. 7: 54-8. PMID: 17347079
- Ximelagatran increases membrane fluidity and changes membrane lipid composition in primary human hepatocytes. | Sergent, O., et al. 2009. Toxicol In Vitro. 23: 1305-10. PMID: 19616086
- Synthesis of ximelagatran, melagatran, hydroxymelagatran, and ethylmelagatran in H-3 labeled form. | Simonsson, R., et al. 2013. J Labelled Comp Radiopharm. 56: 334-7. PMID: 24285415
- In Silico and In Vitro Analysis of Interaction between Ximelagatran and Human Leukocyte Antigen (HLA)-DRB1*07:01. | Hirasawa, M., et al. 2017. Int J Mol Sci. 18: PMID: 28338626
Inhibitor of:
Thrombin.Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
Ximelagatran, 2.5 mg | sc-208491 | 2.5 mg | $398.00 | |||
Ximelagatran, 5 mg | sc-208491A | 5 mg | $707.00 | |||
Ximelagatran, 10 mg | sc-208491B | 10 mg | $1326.00 | |||
Ximelagatran, 25 mg | sc-208491C | 25 mg | $2907.00 | |||
Ximelagatran, 1 g | sc-208491D | 1 g | $10710.00 |